GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.

Marco Castellana Angelo CignarelliFrancesco BresciaLuigi Laviola Francesco Giorgino

Published in: Diabetes/metabolism research and reviews (2018)

The present review supports treatment intensification with GLP-1RA added to insulin versus BP/BB in uncontrolled type 2 diabetes. This could provide similar antihyperglycaemic efficacy while leading to weight loss and sparing of hypoglycaemia and insulin dose. As a consequence, a considerable number of patients with type 2 diabetes could be potentially shifted from BP/BB to GLP-1RA/insulin combinations.

Keyphrases

type diabetes
glycemic control
weight loss
rheumatoid arthritis
cardiovascular disease
insulin resistance
growth factor
stem cells
skeletal muscle
bone marrow
mesenchymal stem cells
systemic lupus erythematosus
minimally invasive